Topic: combination therapy
Data showed a combo of ViiV's cabotegravir and J&J's rilpivirine given very two months was similarly effective to once-monthly Cabenuva.
An FDA approval of Lilly’s Cyramza combo would pit it against AZ's Tagrisso, which has charted impressive survival gains in EGFR-positive lung cancer.
Just days after its first cholesterol-busting drug got the FDA greenlight, Esperion now has a combo therapy approved in the same market.
Pfizer terminated a slew of trial cohorts testing Bavencio in combination with its own experimental drugs, as well as one monotherapy trial.
Buying oncology specialist Array BioPharma is Pfizer CEO Albert Bourla’s biggest M&A move so far. It represents another big bet by the New York drugmaker on cancer treatments since its $14.3 billion deal for Medivation.
The Tecentriq-chemo approval is the second one for the Roche PD-L1 drug in front-line NSCLC, following an OK for a regimen that also contains Avastin.
With a big head-to-head survival win, Roche is coming after Bayer's standard-of-care Nexavar in front-line liver cancer.
Vertex is in the early stages of its triple combo launch Trikafta, which the company believes can treat up to 90% of cystic fibrosis patients.
It’s been a rocky road for BMS’ immuno-oncology duo in previously untreated lung cancer, but a new addition to the regimen might hold the ticket.
The triple combo era in cystic fibrosis, thanks to Vertex and an FDA green light for its next big blockbuster hope, Trikafta.